| Literature DB >> 19468324 |
Paula Amador1,2,3, Ruben Fernandes2, Cristina Prudêncio2, Luísa Brito1.
Abstract
The purpose of this study was to investigate the presence of beta-lactam-resistant bacteria in six different types of Portuguese cheese. The numbers of ampicillin resistant (AMP(r)) bacteria varied from 4.7 x 10(2) to 1.5 x 10(7) CFU/g. Within 172 randomly selected beta-lactam-resistant bacteria, 44 resistant phenotypes were found and 31.4% were multidrug resistant. The majority (85%) of the isolates identified belonged to the Enterobacteriaceae family. The presence of the bla(TEM) gene was detected in 80.9% of the tested isolates. The results suggest that without thermal processing of the milk and good hygienic practices, cheese may act as a vehicle of transfer of beta-lactam-resistant bacteria to the gastrointestinal tract of consumers.Entities:
Keywords: Ready-to-eat (RTE) food; blaTEM gene; cheese, minimal inhibitory concentration (MIC); multiplex-PCR; β-lactam-resistant Enterobacteriaceae
Mesh:
Substances:
Year: 2009 PMID: 19468324 PMCID: PMC2680632 DOI: 10.3390/ijms10041538
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Characterization of the cheeses analyzed with respect to the origin and thermal processing of the milk.
| Type of cheese | Number of cheeses | ||
|---|---|---|---|
| Origin | Thermal processing | ||
| A | ewe | no | 2 |
| B | ewe | no | 13 |
| C | goat | no | 2 |
| D | goat | pasteurization | 1 |
| E | cow | pasteurization | 1 |
| F | mixture (cow, ewe and goat) | no | 1 |
DOP (Denomination of Protected Origin).
Figure 1.Mean values of ampicillin resistant (AMPr) bacteria (CFU/g of cheese) ± the standard deviation (error bars), on VRBG agar medium, after 38 hours at 37 ºC.
Identification of 60 AMPr isolates positive for the nitrocefin test, and respective type of cheese and recovery medium.
| Family/Genus | Species | Number of isolates | % | Type of cheese | Recovery medium |
|---|---|---|---|---|---|
| Enterobacteriaceae | NI | 17 | 28.3 | A, B, C, D | VRBG, SS |
| 9 | 15.0 | B, C, F | VRBG, SS | ||
| 6 | 10.0 | B, D, F | VRBG, SS | ||
| 6 | 10 | B, C, F | VRBG, SS | ||
| 4 | 6.7 | A, B, F | VRBG | ||
| 2 | 3.3 | B, F | VRBG | ||
| 2 | 3.3 | A | SS | ||
| 1 | 1.7 | B | VRBG | ||
| 1 | 1.7 | B | VRBG | ||
| 1 | 1.7 | B | VRBG | ||
| 1 | 1.7 | B | SS | ||
| 1 | 1.7 | D | SS | ||
| NI | 5 | 8.3 | B, C | VRBG, SS | |
| NI | 4 | 6.7 | B, C, D | VRBG, SS | |
| All | 60 | 100 | A, B, C, D, F | VRBG, SS |
Legend: Medium VRBG – Violet Red Bile Glucose; Medium SS – Salmonella/Shigella. NI – Not identified.
Minimal inhibitory concentrations (MIC) for the antimicrobial agents tested and percentage of the resistance or susceptible phenotype obtained among the isolated AMPr/nitrocefin positive strains (n = 172).
| Antimicrobial agent | Φ | MIC | % | Φ | MIC | n | % | ||
|---|---|---|---|---|---|---|---|---|---|
| (mm) | (μg/mL) | ( | (mm) | (μg/mL) | ( | ||||
| AMC (30:10 μg) | ≥ 18 | ≤ 8/4 | 67 | 39.0 | ≤ 13 | ≥ 32/16 | 89 | 51.7 | |
| FOX (30 μg) | ≥ 18 | ≤ 8 | 70 | 40.7 | ≤ 14 | ≥ 32 | 80 | 46.5 | |
| CTX (30 μg) | ≥ 23 | ≤ 8 | 115 | 66.9 | ≤ 14 | ≥ 32 | 23 | 13.4 | |
| CPO (30 μg) | ≥ 18 | ≤ 8 | 150 | 87.2 | ≤ 14 | ≥ 32 | 10 | 5.8 | |
| ATM (30 μg) | ≥ 22 | ≤ 8 | 142 | 82.6 | ≤ 15 | ≥ 32 | 10 | 5.8 | |
| CAZ (30 μg) | ≥ 18 | ≤ 8 | 158 | 91.9 | ≤ 14 | ≥ 32 | 9 | 5.2 | |
| MEM (10 μg) | ≥ 16 | ≤ 4 | 156 | 90.7 | ≤ 13 | ≥ 16 | 9 | 5.2 | |
| IPM (10 μg) | ≥ 16 | ≤ 4 | 164 | 95.3 | ≤ 13 | ≥ 16 | 2 | 1.2 | |
| TET (30 μg) | ≥ 19 | ≤ 4 | 56 | 32.6 | ≤ 14 | ≥ 16 | 80 | 46.5 | |
| SXT (1:19 μg) | ≥ 16 | ≤ 2/38 | 103 | 59.9 | ≤ 10 | ≥ 8/152 | 66 | 38.4 | |
| CHL (30 μg) | ≥ 18 | ≤ 8 | 108 | 62.8 | ≤ 12 | ≥ 32 | 35 | 20.3 | |
| GEN (10 μg) | ≥ 15 | ≤ 4 | 169 | 98.3 | ≤ 12 | ≥ 8 | 3 | 1.7 | |
| CIP (5 μg) | ≥ 21 | ≤ 1 | 168 | 97.7 | ≤ 15 | ≥ 4 | 0 | 0.0 | |
MIC values were determined after conversion of the respective diameters obtained from the disc diffusion antimicrobial susceptibility testing from CLSI standards [15,16].
Prevalence of resistance phenotypes to major antimicrobial classes among 172 nitocefin positive isolates.
| Resistance Phenotype | Number of isolates | % | |
|---|---|---|---|
| AMP, SXT, TET | 8 | 4.65 | |
| AMP, AMC, FOX, SXT, TET | 8 | 4.65 | |
| AMP, AMC, FOX, CHL, TET | 7 | 4.07 | |
| AMP, AMC, FOX, CHL, SXT, TET | 4 | 2.33 | |
| AMP, AMC, FOX, CHL, SXT | 4 | 2.33 | |
| AMP, AMC, CHL, TET | 2 | 1.16 | |
| AMP, CHL, SXT, TET | 2 | 1.16 | |
| AMP, AMC, SXT, TET | 2 | 1.16 | |
| AMP, AMC, CHL, SXT, TET | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, CPO, CHL, SXT, TET | 2 | 1.16 | |
| AMP, CHL, TET | 2 | 1.16 | |
| AMP, FOX, CHL, TET | 2 | 1.16 | |
| Others with only one representative | 9 | 5,22 | |
| 54 | 31.40 | ||
| AMP | 38 | 22.09 | |
| AMP, TET | 19 | 11.05 | |
| AMP, AMC, FOX, SXT | 8 | 4.65 | |
| AMP, AMC, FOX, TET | 7 | 4.07 | |
| AMP, AMC, FOX | 6 | 3.49 | |
| AMP, AMC, TET | 5 | 2.91 | |
| AMP, SXT | 5 | 2.91 | |
| AMP, AMC | 4 | 2.33 | |
| AMP, AMC, FOX, CEPH3, ATM | 4 | 2.33 | |
| AMP, AMC, FOX, CEPH3, CPO, ATM | 4 | 2.33 | |
| AMP, FOX, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, CARB, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, CEPH3, CPO, CARB, SXT | 2 | 1.16 | |
| AMP, AMC, FOX, SXT | 2 | 1.16 | |
| Others with only one representative | 8 | 4.64 | |
| 118 | 68.60 | ||
| 172 | 100 | ||